Background: As it is obvious, there is much documentation that shows
the importance of breast cancer treatment in patients. High expressions of P53 and
Bcl-2 are associated with breast cancer, which are reliable factors to follow up the
breast cancer. Berberis vulgaris is used as a traditional medicine in cancer. Despite
of the fact that many researches have demonstrated its anti-cancer properties, there
are no scientific documents to show its efficacy in detail in breast cancer.
Objective: Because of traditional use of B. vulgaris and little knowledge about its effects,
our research was focused on determining the efficacy and toxicity of B. vulgaris.
For this reason, we determined the efficacy of B. vulgaris on breast cancer cells.
Method: As described in Method section, standard protocols including MTT assay
and qPCR were performed to identify the effect of B. vulgaris ethanolic extract
against breast cancer cells.
Results: Our results clearly demonstrated that 35 mg/ml had IC50 against 3t3 normal
cells, and 9 mg/ml of B. vulgaris was effective against MCF-7 breast cancer cells.
The results demonstrated that even at only 1 mg/ml concentration of B. vulgaris,
crude extract was effective, 9 mg/ml and 12 mg/ml of extract had better anti-cancer
activity compared with doxorubicin.
Conclusion: Despite that the role of anticancer properties of B. vulgaris was clearly
defined in some patents, our results demonstrated the potency of B. vulgaris against
breast cancer, but further analysis should be performed to candidate this herb as an
anti-breast cancer drug.